Swiss National Bank
MLYS icon

Swiss National Bank’s Mineralys Therapeutics MLYS Stock Holding History

Swiss National Bank’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.44M Hold
90,100
– – ﹤0.01% 1750
2025
Q4 		$3.27M Buy
90,100
+1,600
+2% +$64.2K ﹤0.01% 1602
2025
Q3 		$3.36M Buy
88,500
+26,600
+43% +$575K ﹤0.01% 1564
2025
Q2 		$838K Buy
+61,900
New +$897K ﹤0.01% 2207

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Swiss National Bank's MLYS Position: Q1 2026 in Review

Swiss National Bank held its Mineralys Therapeutics (MLYS) position steady in Q1 2026 at 90,100 shares worth $2.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1750.

Swiss National Bank first reported a position in MLYS in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.36M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Swiss National Bank held 90,100 shares of Mineralys Therapeutics worth $2.44M as of Q1 2026.
  • Swiss National Bank left its Mineralys Therapeutics share count unchanged in Q1 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1750 holding.
  • Swiss National Bank first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Swiss National Bank's Mineralys Therapeutics position peaked at $3.36M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.